Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 33 | 2023 | 406 | 7.330 |
Why?
|
Nitrates | 12 | 2013 | 35 | 3.270 |
Why?
|
Nitrites | 11 | 2015 | 30 | 2.920 |
Why?
|
Lymphoma, Non-Hodgkin | 14 | 2013 | 261 | 2.720 |
Why?
|
Diet | 14 | 2015 | 442 | 2.430 |
Why?
|
Survivors | 7 | 2016 | 225 | 1.810 |
Why?
|
Carcinoma, Papillary | 14 | 2023 | 158 | 1.620 |
Why?
|
Carcinoma | 10 | 2015 | 434 | 1.580 |
Why?
|
Occupational Exposure | 4 | 2017 | 80 | 1.540 |
Why?
|
Air Pollution | 3 | 2023 | 68 | 1.290 |
Why?
|
Air Pollutants | 3 | 2024 | 78 | 1.270 |
Why?
|
Quality of Life | 7 | 2018 | 1575 | 1.230 |
Why?
|
Population Health | 2 | 2022 | 33 | 1.080 |
Why?
|
Middle Aged | 60 | 2024 | 24957 | 1.080 |
Why?
|
Meat | 6 | 2013 | 26 | 1.070 |
Why?
|
Adenocarcinoma, Follicular | 8 | 2016 | 51 | 1.050 |
Why?
|
Occupations | 2 | 2014 | 26 | 1.000 |
Why?
|
Occupational Diseases | 2 | 2014 | 55 | 0.960 |
Why?
|
Incidence | 16 | 2018 | 1568 | 0.930 |
Why?
|
United States | 30 | 2023 | 6637 | 0.890 |
Why?
|
Humans | 92 | 2024 | 86281 | 0.890 |
Why?
|
Polymorphism, Single Nucleotide | 9 | 2016 | 2350 | 0.890 |
Why?
|
Aged | 44 | 2023 | 18353 | 0.890 |
Why?
|
Insurance Coverage | 1 | 2023 | 115 | 0.880 |
Why?
|
Case-Control Studies | 20 | 2023 | 1801 | 0.870 |
Why?
|
Environmental Exposure | 4 | 2023 | 296 | 0.860 |
Why?
|
Adult | 51 | 2024 | 25577 | 0.840 |
Why?
|
Cohort Studies | 14 | 2023 | 2759 | 0.830 |
Why?
|
Female | 67 | 2024 | 44405 | 0.830 |
Why?
|
Sex Factors | 13 | 2015 | 1053 | 0.830 |
Why?
|
Smoking | 7 | 2013 | 605 | 0.810 |
Why?
|
Chicago | 9 | 2024 | 1377 | 0.790 |
Why?
|
SEER Program | 13 | 2016 | 181 | 0.770 |
Why?
|
Male | 57 | 2023 | 40860 | 0.740 |
Why?
|
Global Health | 3 | 2018 | 193 | 0.740 |
Why?
|
Medicare | 1 | 2023 | 404 | 0.740 |
Why?
|
Risk Factors | 23 | 2015 | 5397 | 0.740 |
Why?
|
Cancer Survivors | 2 | 2018 | 85 | 0.700 |
Why?
|
Prevalence | 10 | 2024 | 1239 | 0.670 |
Why?
|
Neoplasms | 7 | 2022 | 2889 | 0.660 |
Why?
|
Age Factors | 13 | 2015 | 1842 | 0.580 |
Why?
|
Meat Products | 3 | 2012 | 7 | 0.570 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 826 | 0.560 |
Why?
|
Genotype | 5 | 2015 | 1850 | 0.560 |
Why?
|
Aged, 80 and over | 17 | 2017 | 6481 | 0.560 |
Why?
|
Psychometrics | 1 | 2017 | 327 | 0.560 |
Why?
|
Surveys and Questionnaires | 14 | 2022 | 2495 | 0.540 |
Why?
|
Halogenated Diphenyl Ethers | 1 | 2015 | 3 | 0.540 |
Why?
|
Polybrominated Biphenyls | 1 | 2015 | 5 | 0.540 |
Why?
|
Young Adult | 20 | 2021 | 5961 | 0.530 |
Why?
|
Asthma | 1 | 2023 | 947 | 0.520 |
Why?
|
Parity | 1 | 2015 | 93 | 0.510 |
Why?
|
Spirituality | 1 | 2015 | 87 | 0.510 |
Why?
|
Sezary Syndrome | 1 | 2014 | 8 | 0.510 |
Why?
|
Environmental Pollutants | 1 | 2015 | 50 | 0.510 |
Why?
|
Mycosis Fungoides | 1 | 2014 | 23 | 0.500 |
Why?
|
Hypothyroidism | 2 | 2017 | 232 | 0.500 |
Why?
|
Alcohol Drinking | 2 | 2012 | 264 | 0.500 |
Why?
|
Graves Disease | 1 | 2014 | 36 | 0.490 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2012 | 122 | 0.480 |
Why?
|
Arylamine N-Acetyltransferase | 3 | 2012 | 11 | 0.480 |
Why?
|
Testicular Neoplasms | 4 | 2014 | 104 | 0.480 |
Why?
|
Hypertension | 1 | 2022 | 1139 | 0.470 |
Why?
|
Life Style | 1 | 2014 | 188 | 0.460 |
Why?
|
Health Status | 1 | 2015 | 360 | 0.460 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2013 | 35 | 0.440 |
Why?
|
Social Behavior | 1 | 2015 | 294 | 0.440 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2012 | 62 | 0.430 |
Why?
|
Water Wells | 1 | 2012 | 18 | 0.430 |
Why?
|
Particulate Matter | 2 | 2023 | 79 | 0.410 |
Why?
|
Hyperthyroidism | 1 | 2012 | 75 | 0.410 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2012 | 48 | 0.410 |
Why?
|
Air Pollution, Indoor | 2 | 2022 | 61 | 0.400 |
Why?
|
Quantitative Trait Loci | 1 | 2015 | 576 | 0.390 |
Why?
|
Connecticut | 6 | 2012 | 27 | 0.390 |
Why?
|
Breast Neoplasms | 4 | 2023 | 2881 | 0.390 |
Why?
|
Water Pollutants, Chemical | 1 | 2012 | 135 | 0.380 |
Why?
|
Diet Surveys | 4 | 2015 | 20 | 0.380 |
Why?
|
Sexual Dysfunction, Physiological | 3 | 2012 | 67 | 0.380 |
Why?
|
Health Services Accessibility | 1 | 2014 | 392 | 0.370 |
Why?
|
Pancreatic Neoplasms | 2 | 2016 | 645 | 0.360 |
Why?
|
Diabetes Complications | 1 | 2011 | 206 | 0.360 |
Why?
|
Risk | 9 | 2013 | 673 | 0.360 |
Why?
|
Residence Characteristics | 2 | 2022 | 195 | 0.360 |
Why?
|
Endometrial Neoplasms | 1 | 2012 | 191 | 0.340 |
Why?
|
Nitroso Compounds | 3 | 2013 | 12 | 0.330 |
Why?
|
Vegetables | 3 | 2013 | 45 | 0.330 |
Why?
|
Prospective Studies | 7 | 2023 | 4194 | 0.330 |
Why?
|
Phenotype | 1 | 2015 | 2375 | 0.330 |
Why?
|
Fruit | 3 | 2013 | 75 | 0.330 |
Why?
|
Odds Ratio | 4 | 2014 | 677 | 0.320 |
Why?
|
Proportional Hazards Models | 5 | 2013 | 857 | 0.320 |
Why?
|
Smoking Cessation | 4 | 2007 | 230 | 0.310 |
Why?
|
Cytokines | 1 | 2011 | 775 | 0.310 |
Why?
|
Registries | 7 | 2018 | 702 | 0.290 |
Why?
|
China | 6 | 2013 | 228 | 0.290 |
Why?
|
Infertility, Male | 2 | 2011 | 24 | 0.290 |
Why?
|
Multivariate Analysis | 3 | 2015 | 997 | 0.280 |
Why?
|
Pesticides | 2 | 2017 | 28 | 0.270 |
Why?
|
Adolescent | 13 | 2021 | 8968 | 0.270 |
Why?
|
Isoenzymes | 2 | 2012 | 271 | 0.270 |
Why?
|
Models, Statistical | 1 | 2009 | 574 | 0.260 |
Why?
|
Ovarian Neoplasms | 1 | 2012 | 738 | 0.260 |
Why?
|
Linear Models | 3 | 2015 | 419 | 0.260 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2016 | 109 | 0.250 |
Why?
|
Resistin | 1 | 2023 | 14 | 0.240 |
Why?
|
Ghrelin | 1 | 2023 | 29 | 0.240 |
Why?
|
Troponin | 1 | 2023 | 24 | 0.240 |
Why?
|
Survival Rate | 6 | 2016 | 1856 | 0.230 |
Why?
|
Medically Uninsured | 1 | 2023 | 58 | 0.230 |
Why?
|
Diabetes Mellitus | 1 | 2011 | 801 | 0.230 |
Why?
|
C-Peptide | 1 | 2023 | 174 | 0.230 |
Why?
|
Leptin | 1 | 2023 | 105 | 0.230 |
Why?
|
Metabolome | 1 | 2023 | 47 | 0.220 |
Why?
|
Insurance, Health | 1 | 2023 | 158 | 0.220 |
Why?
|
Logistic Models | 7 | 2024 | 1184 | 0.220 |
Why?
|
Interleukin-6 | 1 | 2023 | 255 | 0.210 |
Why?
|
Ambulatory Care | 1 | 2023 | 180 | 0.210 |
Why?
|
Electronic Health Records | 2 | 2022 | 319 | 0.210 |
Why?
|
Feeding Behavior | 3 | 2013 | 324 | 0.210 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2022 | 57 | 0.210 |
Why?
|
Fetal Development | 1 | 2021 | 30 | 0.200 |
Why?
|
Premature Birth | 1 | 2023 | 112 | 0.200 |
Why?
|
Family Health | 2 | 2008 | 162 | 0.200 |
Why?
|
Socioeconomic Factors | 2 | 2015 | 567 | 0.200 |
Why?
|
Medicaid | 1 | 2023 | 216 | 0.190 |
Why?
|
Cooking | 1 | 2021 | 53 | 0.190 |
Why?
|
Follow-Up Studies | 7 | 2016 | 3616 | 0.190 |
Why?
|
Infant, Newborn | 4 | 2023 | 2369 | 0.190 |
Why?
|
Europe | 3 | 2014 | 308 | 0.190 |
Why?
|
Poverty Areas | 1 | 2020 | 37 | 0.190 |
Why?
|
Leiomyoma | 1 | 2024 | 189 | 0.190 |
Why?
|
Child | 6 | 2013 | 6913 | 0.190 |
Why?
|
Cleft Lip | 1 | 2010 | 15 | 0.180 |
Why?
|
Uterine Neoplasms | 1 | 2024 | 225 | 0.180 |
Why?
|
Educational Status | 2 | 2022 | 187 | 0.180 |
Why?
|
Genetic Predisposition to Disease | 7 | 2012 | 2267 | 0.180 |
Why?
|
Cleft Palate | 1 | 2010 | 25 | 0.180 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 683 | 0.180 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 47 | 0.180 |
Why?
|
Fertility | 1 | 2010 | 111 | 0.180 |
Why?
|
Glutathione Transferase | 1 | 2010 | 111 | 0.180 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2010 | 79 | 0.180 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2009 | 7 | 0.180 |
Why?
|
Practice Patterns, Physicians' | 2 | 2015 | 578 | 0.180 |
Why?
|
Glutathione S-Transferase pi | 1 | 2009 | 18 | 0.180 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 44 | 0.170 |
Why?
|
Primary Health Care | 1 | 2022 | 339 | 0.170 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2010 | 164 | 0.170 |
Why?
|
Nitric Oxide Synthase | 1 | 2009 | 125 | 0.170 |
Why?
|
Counseling | 2 | 2007 | 144 | 0.170 |
Why?
|
Prognosis | 7 | 2016 | 3669 | 0.170 |
Why?
|
Physicians | 2 | 2018 | 672 | 0.170 |
Why?
|
Fluorosis, Dental | 1 | 2008 | 2 | 0.160 |
Why?
|
Biomedical Research | 1 | 2022 | 375 | 0.160 |
Why?
|
Lymphoma, Follicular | 2 | 2014 | 70 | 0.160 |
Why?
|
Cross-Sectional Studies | 4 | 2020 | 1610 | 0.160 |
Why?
|
Biomarkers, Tumor | 3 | 2016 | 1461 | 0.160 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 387 | 0.160 |
Why?
|
Glioma | 1 | 2010 | 285 | 0.160 |
Why?
|
Genome-Wide Association Study | 2 | 2016 | 1611 | 0.160 |
Why?
|
Agricultural Workers' Diseases | 1 | 2017 | 18 | 0.160 |
Why?
|
State Health Plans | 1 | 2007 | 14 | 0.150 |
Why?
|
Smoking Prevention | 1 | 2007 | 43 | 0.150 |
Why?
|
Alcoholic Beverages | 2 | 2012 | 13 | 0.150 |
Why?
|
Food | 2 | 2012 | 85 | 0.150 |
Why?
|
Biomarkers | 1 | 2023 | 1709 | 0.150 |
Why?
|
Social Perception | 1 | 2018 | 95 | 0.150 |
Why?
|
Bangladesh | 2 | 2015 | 318 | 0.150 |
Why?
|
Chronic Disease | 1 | 2020 | 968 | 0.150 |
Why?
|
Blood Pressure | 1 | 2022 | 1143 | 0.150 |
Why?
|
Nonprescription Drugs | 1 | 2006 | 15 | 0.150 |
Why?
|
Pharmacists | 1 | 2006 | 32 | 0.150 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2010 | 376 | 0.140 |
Why?
|
Collagen | 1 | 2008 | 268 | 0.140 |
Why?
|
DNA Methylation | 2 | 2023 | 622 | 0.140 |
Why?
|
Lymphoma | 1 | 2008 | 262 | 0.140 |
Why?
|
Students | 1 | 2007 | 146 | 0.140 |
Why?
|
Patient Selection | 1 | 2020 | 685 | 0.140 |
Why?
|
Cost of Illness | 2 | 2013 | 150 | 0.140 |
Why?
|
Ultraviolet Rays | 1 | 2007 | 193 | 0.140 |
Why?
|
Disease-Free Survival | 3 | 2016 | 1203 | 0.140 |
Why?
|
Confidence Intervals | 2 | 2011 | 228 | 0.140 |
Why?
|
Rare Diseases | 1 | 2016 | 59 | 0.140 |
Why?
|
Parathyroid Neoplasms | 1 | 2016 | 55 | 0.140 |
Why?
|
Health Promotion | 1 | 2007 | 160 | 0.130 |
Why?
|
Chromatography, Gas | 1 | 2015 | 28 | 0.130 |
Why?
|
Thyrotropin | 2 | 2017 | 280 | 0.130 |
Why?
|
Canada | 1 | 2015 | 204 | 0.130 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2016 | 80 | 0.130 |
Why?
|
Epigenomics | 1 | 2016 | 98 | 0.130 |
Why?
|
Polymorphism, Genetic | 1 | 2009 | 819 | 0.130 |
Why?
|
Age of Onset | 1 | 2015 | 306 | 0.130 |
Why?
|
Drinking Water | 2 | 2013 | 64 | 0.130 |
Why?
|
Tobacco Use Disorder | 1 | 2006 | 108 | 0.130 |
Why?
|
Nicotine | 1 | 2006 | 193 | 0.130 |
Why?
|
Women's Health | 2 | 2013 | 100 | 0.130 |
Why?
|
Thyroid Nodule | 1 | 2015 | 51 | 0.130 |
Why?
|
Carcinoma, Neuroendocrine | 2 | 2013 | 28 | 0.130 |
Why?
|
Activities of Daily Living | 1 | 2015 | 202 | 0.130 |
Why?
|
Mass Spectrometry | 1 | 2015 | 188 | 0.130 |
Why?
|
Brain Neoplasms | 1 | 2010 | 763 | 0.120 |
Why?
|
Survival Analysis | 3 | 2014 | 1536 | 0.120 |
Why?
|
Databases, Factual | 1 | 2018 | 808 | 0.120 |
Why?
|
Australia | 1 | 2014 | 99 | 0.120 |
Why?
|
Time Factors | 3 | 2011 | 5198 | 0.120 |
Why?
|
North America | 1 | 2014 | 179 | 0.120 |
Why?
|
Agriculture | 1 | 2014 | 38 | 0.120 |
Why?
|
Food Contamination | 1 | 2013 | 31 | 0.120 |
Why?
|
Health Transition | 1 | 2013 | 2 | 0.120 |
Why?
|
Patient Outcome Assessment | 1 | 2014 | 83 | 0.120 |
Why?
|
Adenoma | 1 | 2015 | 234 | 0.120 |
Why?
|
Oryza | 1 | 2013 | 40 | 0.120 |
Why?
|
Developed Countries | 1 | 2013 | 24 | 0.120 |
Why?
|
Infant | 2 | 2010 | 3036 | 0.120 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 136 | 0.110 |
Why?
|
Diet, Western | 1 | 2013 | 37 | 0.110 |
Why?
|
Phytanic Acid | 1 | 2012 | 3 | 0.110 |
Why?
|
Child, Preschool | 2 | 2010 | 3608 | 0.110 |
Why?
|
Developing Countries | 1 | 2013 | 69 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 2 | 2013 | 859 | 0.110 |
Why?
|
Oleic Acid | 1 | 2012 | 14 | 0.110 |
Why?
|
Mutagens | 1 | 2012 | 31 | 0.110 |
Why?
|
Food Analysis | 1 | 2012 | 4 | 0.110 |
Why?
|
Costs and Cost Analysis | 1 | 2013 | 153 | 0.110 |
Why?
|
Genetic Variation | 1 | 2009 | 1349 | 0.110 |
Why?
|
Libido | 1 | 2012 | 8 | 0.110 |
Why?
|
Penile Erection | 1 | 2012 | 22 | 0.110 |
Why?
|
Quinoxalines | 1 | 2012 | 50 | 0.110 |
Why?
|
Amish | 1 | 2012 | 6 | 0.110 |
Why?
|
Pharmacies | 1 | 2012 | 6 | 0.110 |
Why?
|
Pennsylvania | 1 | 2012 | 75 | 0.110 |
Why?
|
Epidemiological Monitoring | 1 | 2012 | 39 | 0.100 |
Why?
|
Commerce | 1 | 2012 | 29 | 0.100 |
Why?
|
Health Personnel | 1 | 2014 | 202 | 0.100 |
Why?
|
Dietary Fats | 1 | 2012 | 134 | 0.100 |
Why?
|
Environmental Monitoring | 1 | 2012 | 71 | 0.100 |
Why?
|
Eating | 1 | 2012 | 166 | 0.100 |
Why?
|
Health Care Costs | 1 | 2013 | 237 | 0.100 |
Why?
|
Thyroid Carcinoma, Anaplastic | 1 | 2010 | 11 | 0.100 |
Why?
|
Genomic Instability | 1 | 2011 | 79 | 0.100 |
Why?
|
Arsenic | 1 | 2013 | 251 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2012 | 177 | 0.100 |
Why?
|
Comorbidity | 1 | 2014 | 943 | 0.100 |
Why?
|
Water Pollutants | 1 | 2010 | 2 | 0.100 |
Why?
|
Health Surveys | 1 | 2011 | 238 | 0.090 |
Why?
|
Pregnancy | 3 | 2023 | 2885 | 0.090 |
Why?
|
Neoplasm Staging | 4 | 2016 | 1932 | 0.090 |
Why?
|
Pregnancy Outcome | 2 | 2023 | 247 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2012 | 170 | 0.090 |
Why?
|
Gene Frequency | 1 | 2011 | 676 | 0.090 |
Why?
|
Carcinoma, Medullary | 1 | 2009 | 11 | 0.090 |
Why?
|
Sexual Behavior | 1 | 2012 | 301 | 0.090 |
Why?
|
Clinical Competence | 1 | 2014 | 750 | 0.080 |
Why?
|
Sex Characteristics | 1 | 2010 | 319 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2012 | 425 | 0.080 |
Why?
|
Diet Records | 2 | 2012 | 19 | 0.080 |
Why?
|
Retrospective Studies | 4 | 2016 | 8431 | 0.080 |
Why?
|
Kidney Neoplasms | 1 | 2012 | 620 | 0.070 |
Why?
|
Sex Distribution | 2 | 2008 | 173 | 0.070 |
Why?
|
Risk Assessment | 2 | 2011 | 2253 | 0.070 |
Why?
|
Age Distribution | 2 | 2008 | 204 | 0.070 |
Why?
|
Aging | 1 | 2011 | 689 | 0.070 |
Why?
|
Models, Genetic | 1 | 2011 | 926 | 0.070 |
Why?
|
Colorectal Neoplasms | 1 | 2013 | 924 | 0.070 |
Why?
|
Water Supply | 2 | 2010 | 60 | 0.070 |
Why?
|
Lung Neoplasms | 1 | 2007 | 2260 | 0.060 |
Why?
|
Cell Differentiation | 1 | 2011 | 1456 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2022 | 1015 | 0.060 |
Why?
|
Biopsy, Fine-Needle | 2 | 2015 | 93 | 0.060 |
Why?
|
Iowa | 2 | 2017 | 35 | 0.060 |
Why?
|
Cause of Death | 2 | 2013 | 277 | 0.060 |
Why?
|
Stillbirth | 1 | 2023 | 9 | 0.060 |
Why?
|
Infant, Low Birth Weight | 1 | 2023 | 58 | 0.060 |
Why?
|
Metabolomics | 1 | 2023 | 67 | 0.060 |
Why?
|
Family Characteristics | 1 | 2022 | 46 | 0.050 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 137 | 0.050 |
Why?
|
Kerosene | 1 | 2021 | 17 | 0.050 |
Why?
|
Islam | 1 | 2022 | 34 | 0.050 |
Why?
|
Wood | 1 | 2021 | 19 | 0.050 |
Why?
|
Maternal-Fetal Exchange | 1 | 2021 | 76 | 0.050 |
Why?
|
Housing | 1 | 2021 | 42 | 0.050 |
Why?
|
Fetal Growth Retardation | 1 | 2021 | 66 | 0.050 |
Why?
|
Maternal Exposure | 1 | 2021 | 57 | 0.050 |
Why?
|
Nigeria | 1 | 2021 | 152 | 0.050 |
Why?
|
Food Handling | 1 | 2010 | 5 | 0.050 |
Why?
|
Data Collection | 1 | 2022 | 371 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2014 | 7949 | 0.050 |
Why?
|
Databases as Topic | 1 | 2010 | 92 | 0.050 |
Why?
|
Biotransformation | 1 | 2010 | 50 | 0.050 |
Why?
|
Ultrasonography, Prenatal | 1 | 2021 | 152 | 0.050 |
Why?
|
Fetus | 1 | 2021 | 226 | 0.050 |
Why?
|
Carcinogens | 1 | 2010 | 108 | 0.040 |
Why?
|
Lymphoma, T-Cell | 1 | 2010 | 48 | 0.040 |
Why?
|
Cytochrome P-450 CYP1B1 | 1 | 2009 | 9 | 0.040 |
Why?
|
Medical Records | 1 | 2010 | 119 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2022 | 237 | 0.040 |
Why?
|
Neonatal Screening | 1 | 2010 | 59 | 0.040 |
Why?
|
Ethanol | 1 | 2021 | 246 | 0.040 |
Why?
|
Asia | 1 | 2008 | 94 | 0.040 |
Why?
|
Africa | 1 | 2008 | 98 | 0.040 |
Why?
|
Procollagen | 1 | 2008 | 8 | 0.040 |
Why?
|
DNA-Cytosine Methylases | 1 | 2008 | 4 | 0.040 |
Why?
|
Osteocalcin | 1 | 2008 | 26 | 0.040 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 2008 | 30 | 0.040 |
Why?
|
Calcitonin | 1 | 2008 | 38 | 0.040 |
Why?
|
Population Surveillance | 1 | 2009 | 219 | 0.040 |
Why?
|
Genetic Association Studies | 1 | 2010 | 294 | 0.040 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2008 | 147 | 0.040 |
Why?
|
Collagen Type I | 1 | 2008 | 62 | 0.040 |
Why?
|
World Health Organization | 1 | 2008 | 103 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2009 | 297 | 0.040 |
Why?
|
Taxes | 1 | 2007 | 3 | 0.040 |
Why?
|
North Carolina | 1 | 2017 | 49 | 0.040 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2009 | 151 | 0.040 |
Why?
|
Behavior Therapy | 1 | 2007 | 75 | 0.040 |
Why?
|
DNA | 1 | 2023 | 1293 | 0.040 |
Why?
|
Community Pharmacy Services | 1 | 2006 | 5 | 0.040 |
Why?
|
Urban Population | 1 | 2008 | 213 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2007 | 188 | 0.040 |
Why?
|
Genetic Markers | 1 | 2008 | 476 | 0.040 |
Why?
|
Administration, Cutaneous | 1 | 2006 | 58 | 0.040 |
Why?
|
Qualitative Research | 1 | 2018 | 256 | 0.040 |
Why?
|
Health Education | 1 | 2007 | 100 | 0.040 |
Why?
|
California | 1 | 2006 | 138 | 0.040 |
Why?
|
Nurse's Role | 1 | 2006 | 12 | 0.040 |
Why?
|
Reactive Oxygen Species | 1 | 2009 | 480 | 0.040 |
Why?
|
Substance Abuse Detection | 1 | 2006 | 12 | 0.040 |
Why?
|
Nursing Assessment | 1 | 2006 | 20 | 0.040 |
Why?
|
Autoantibodies | 1 | 2017 | 267 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2009 | 446 | 0.030 |
Why?
|
Calibration | 1 | 2015 | 99 | 0.030 |
Why?
|
Triiodothyronine | 1 | 2017 | 339 | 0.030 |
Why?
|
Thyroxine | 1 | 2017 | 344 | 0.030 |
Why?
|
CpG Islands | 1 | 2016 | 150 | 0.030 |
Why?
|
Alleles | 1 | 2009 | 1127 | 0.030 |
Why?
|
Thyroidectomy | 1 | 2016 | 170 | 0.030 |
Why?
|
Tertiary Care Centers | 1 | 2015 | 93 | 0.030 |
Why?
|
Finland | 1 | 2014 | 29 | 0.030 |
Why?
|
Thyroid Gland | 1 | 2016 | 270 | 0.030 |
Why?
|
Incidental Findings | 1 | 2015 | 95 | 0.030 |
Why?
|
Public Health | 1 | 2006 | 129 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2018 | 452 | 0.030 |
Why?
|
Communication | 1 | 2018 | 438 | 0.030 |
Why?
|
Health Policy | 1 | 2006 | 180 | 0.030 |
Why?
|
Ascorbic Acid | 1 | 2013 | 37 | 0.030 |
Why?
|
Algorithms | 1 | 2022 | 1828 | 0.030 |
Why?
|
Adenoma, Oxyphilic | 1 | 2013 | 28 | 0.030 |
Why?
|
Social Class | 1 | 2014 | 127 | 0.030 |
Why?
|
Spatio-Temporal Analysis | 1 | 2013 | 21 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2006 | 351 | 0.030 |
Why?
|
Iodine | 1 | 2013 | 40 | 0.030 |
Why?
|
Brazil | 1 | 2013 | 69 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 329 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2013 | 111 | 0.030 |
Why?
|
Nutritional Status | 1 | 2013 | 83 | 0.030 |
Why?
|
Nebraska | 1 | 2012 | 14 | 0.030 |
Why?
|
Critical Care | 1 | 2006 | 368 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 636 | 0.030 |
Why?
|
Ultrasonography | 1 | 2015 | 695 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 610 | 0.030 |
Why?
|
Los Angeles | 1 | 2012 | 28 | 0.030 |
Why?
|
Skin Diseases | 1 | 2013 | 166 | 0.030 |
Why?
|
Mutation | 1 | 2023 | 3952 | 0.030 |
Why?
|
Sickness Impact Profile | 1 | 2011 | 27 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 427 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2006 | 1796 | 0.020 |
Why?
|
Military Personnel | 1 | 2011 | 85 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2015 | 2699 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 927 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2011 | 689 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2011 | 1381 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 2594 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 3347 | 0.010 |
Why?
|